Patients with asthma and allergic bronchopulmonary aspergillosis experienced improvements with dupilumab, according to data presented at the American Thoracic Society International Conference.Quality ...

Allergic bronchopulmonary aspergillosis occurs in patients with bronchial asthma or cystic fibrosis. This case series explores its clinical presentation and diagnostic challenges.

The cutoff value of IgE has been proposed as 1000 IU/ml pending further validation, as it can help in differentiating severe asthma with fungal sensitization from ABPA-S. Minor criteria have been ...

BOSTON — Symptoms improved with mepolizumab after treatment with omalizumab failed for a patient with asthma who developed allergic bronchopulmonary aspergillosis, according to a poster ...

Shocking rise in asthma cases during monsoon! Factors like humidity, mold, and allergens are triggering severe symptoms. Learn how to manage asthma effectively to avoid discomfort and potential ...

One study calculated that 2.5% of adults who have asthma also have ABPA, which is approximately 4.8 million people worldwide. Of these 4.8 million people who have ABPA, an estimated 400,000 also ...

Pulmatrix has an ongoing Phase 2b proof-of-concept clinical trial in adults with ABPA and asthma with sites in in the United States, Australia, France, and the United Kingdom.

Endpoints include safety, tolerability, and potential efficacy outcomes in adult patients with asthma and ABPA. The study has dosed the first of 30 planned study subjects.

One study calculated that 2.5% of adults who have asthma also have ABPA, which is approximately 4.8 million people worldwide.